

# **Leukaemia & Lymphoma NI**

Report and Financial Statements

Period ended 31 March 2020

# Leukaemia & Lymphoma NI

<i>Contents</i>	<i>Page</i>
Legal and administrative information	1
Trustees' report	2
Statement of trustees' responsibilities	11
Independent auditors' report	12
Statement of financial activities	14
Statement of financial position	15
Statement of cash flows	16
Notes on and forming part of the financial statements	17

# Leukaemia & Lymphoma NI

## Legal and administrative information

<b>Directors</b>	Director Director Director Director Director Director Director Director Director	Mr Richard Buchanan (Chairperson) Mr David Montgomery Mr Brendan Kearney Ms Brigid Napier Ms Heather McComb (Treasurer) Professor Curly Morris Professor Terry Lappin Ms Leanne Cascone Mr Rob Cascone
------------------	--	--

<b>Auditors</b>	Hill Vellacott Chartered Accountants Chamber of Commerce House 22 Great Victoria Street Belfast
-----------------	---

<b>Bankers</b>	Ulster Bank Limited City Branch Donegall Square East Belfast
----------------	---

<b>Solicitors</b>	Edwards & Co 28 Hill Street Belfast
-------------------	---

<b>Principal office</b>	Patrick G Johnston Centre for Cancer Research 97 Lisburn Road Belfast BT9 7AE
-------------------------	--

<b>HMRC reference</b>	XN048014
-----------------------	----------

# Leukaemia & Lymphoma NI

## Trustees' report

The trustees have pleasure in submitting their annual report together with the audited financial statements of LLNI for the period ended 31 March 2020.

The trustees have adopted the provisions of the Charities SORP (FRS 102) in preparing their annual report and financial statements of the charity.

Legal and administrative information on page 1 forms part of this report.

## Objectives and activities

Leukaemia & Lymphoma NI is a Limited Company with Charitable status as of April 1<sup>st</sup> 2020. Prior to this it was unincorporated Members Association governed by its Constitution. Its objects are to promote research into the causes and cure of leukaemia, lymphoma and other associated blood cancers in Northern Ireland.

## History of LLNI

Leukaemia & Lymphoma NI (previously Northern Ireland Leukaemia Research Fund) was established in 1964 by the McDowell family following the loss of their daughter Carole to leukaemia. It is supported throughout the province especially by relatives and friends of patients affected by these diseases. Over the last 50 years they have raised in excess of £13 million.

Leukaemia & Lymphoma NI (LLNI) invites applications from scientists and clinicians to apply for grants to investigate some particular aspects of the diseases. LLNI has awarded grants to universities, particularly to Queen's University, Belfast, to establish a Chair of Haematology, to carry out fundamental research on the mechanisms involved in blood formation and the development of leukaemia, lymphoma, myeloma and other associated blood cancers.

All grant applications to LLNI are reviewed by a Medical Advisory Committee, chaired and supported by local and national haematology experts. Grant applications are subjected to rigorous scrutiny in accordance with the guidelines laid down by the Association of Medical Research Charities of which LLNI is a member.

In April 2001 the group moved to the Patrick G Johnston Centre for Cancer Research (previously CCRCB) at Queen's University Belfast which obtained a Grade 5 in the 2001 University Research Assessment Exercise, denoting work of international repute.

It is of great importance to LLNI to determine if the incidence and type of blood cancers is changing throughout the province and to this end a Register of Leukaemia and Lymphoma has been established in collaboration with similar registers throughout the UK. Support from LLNI has enabled the highest standard of care to be available for patients and allow Northern Ireland researchers to make significant contributions to the understanding of the nature of these diseases.

# Leukaemia & Lymphoma NI

## Trustees' report

### **Chairman's Report – Mr Richard Buchanan**

I'm really pleased to be able to report that Leukaemia and Lymphoma NI has had another successful year, raising over £500,000 to fund more brilliant research right here in the Patrick G Johnston Centre for Cancer Research. Each year we are a step closer to making blood cancer history thanks to the support we've had from so many generous donors.

The charity remains absolutely focussed on raising money to spend on scientific research with the aim of improving survival rates and quality of life for blood cancer patients. And we do this by supporting clinicians, scientists and students researching these cancers in Northern Ireland. This takes place under the guidance of the trustees, who make up our committee of which I am chair. We meet every six weeks or so to review all areas of business, with particular focus on finance, fundraising, progress with the science and an overview of the governance of the charity. We have put extra effort this year into ensuring that we are complying fully with relevant legislation and guidance from the Charity Commission for Northern Ireland as we made the transition to private limited company.

If an applicant is interested in applying to obtain funding for a LLNI pilot grant, they are sent the application form and advised to discuss it further with the Chair of the Medical Advisory Committee (MAC). When the completed application is received in the LLNI office, it is passed to the Chair (Professor Terry Lappin) who will work with the office to identify and contact a number of reviewers. These reviewers might be members of the MAC or external reviewers who are experts in the appropriate area. Once the reviewers are received, they are collated and discussed by the MAC and a recommendation made to the Central Committee. In some cases, additional questions and clarification of points raised by the reviewers are addressed with the applicant prior to the recommendation and any further action.

We also consider carefully whether there are other options for funding, in full or in part, and look at options for leveraging funds from elsewhere by making a commitment to a percentage of the total cost of a project. As a committee we are working to improve our scientific knowledge, with regular updates from the scientists to our committee meetings.

We remain a highly efficient charity, with close to 85% of all money raised being spent directly on the science. You will struggle to find another charity of a similar size with such an impressive record of ensuring the money many of you raise is having maximum impact, our relationship with QUB is helpful as our level of financial commitment permits the charity to use their premises which removes a significant overhead from our budget whilst also allowing our team to remain at the heart of the research. We are extremely grateful for the support of Professor Chris Scott, director of the PGJCCR and the rest of the team for their ongoing support in growing our research team.

The day to day running of the charity is looked after by Operations Manager Joanne Badger and the support team of Claire Gilmore and Collette McMorrow.

All of the team do an outstanding job both in the office, raising awareness and support on social media and supporting in person around the country at events and with supporters.

# Leukaemia & Lymphoma NI

## Trustees' report

It makes a real difference to have our office based in the same building where our funded research is taking place, we can demonstrate exactly where each penny raised is going and introduce the experts we fund.

In order to raise awareness of LLNI and blood cancers we have worked with a PR agency on an annual term. This year we worked with ASG to mark our 55<sup>th</sup> anniversary and create our Love Letters Campaign which featured a number of bereaved families throughout NI sharing video messages to loved ones they had lost to blood cancer.

This emotive campaign was scheduled to finish in September 2019 in line with the annual celebration of blood cancer awareness month. This campaign and those before it have been integral in raising the platform of the charity and helping us become the go to organisation for those in NI wanting to support blood cancer research.

After much deliberation we decided to take a step back from the emotive patient stories and look at how supporters respond to showcasing our research. We moved into 2020 in partnership with JMPR and we continue to work with them to spread the message of how we are 'Beating Blood Cancer through Research'.

This year saw many fantastic fundraising events but we were especially pleased to host our own 55<sup>th</sup> Anniversary Love Letters Ball in the Titanic, Belfast in September. This was a great opportunity for our team and supporters to join in a night of celebration which raised over £25,000. This event would not have been possible without the support of Michael Cafolla and his colleagues at the institute of hospitality who very kindly did so much before and during the night.

Our celebrations continued in September as we made it through to the final three charities selected for the Tesco Centenary Fund, after a voting period we were awarded second place and £30,000 towards our 'My Block' project which is looking at the improving outcomes for the more aggressive myeloid cancers.

Interest in our new project had developed throughout the year but at the end of September, a very kind, anonymous donor gifted LLNI £150,000 to accelerate our work on this project. It was another fantastic year for one of our overseas fundraisers; David Henderson originally from Bangor held his 3<sup>rd</sup> annual charity big game fishing tournament in the Bahamas for us, raising close to US\$100,000

Just after Christmas, the Giffin family did their 32nd annual Portrush Walk in memory of their daughter Lynda, bringing the total raised over 32 years to over £200,000.

Into January we started working with JMPR on sharing the message of how we are 'Beating Blood Cancer Through Research', it was our new relationship with JMPR that introduced us to our new Patron, Mr Ken Reid. Ken is a well-known face and voice in NI but he is a wonderful advocate for the work of LLNI as he has personally availed of research developments. Ken is a CML patient who has been part of a trial since diagnosis. We are extremely grateful for his support and the spotlight he has shone on our organisation.

# Leukaemia & Lymphoma NI

## Trustees' report

Our collaboration with the team of Clinical Nurse Specialists in BCH continued as we hosted their annual CML forum in the PGJCCR at the end of January. Building relationships and getting the opportunity to meet with patients is hugely encouraging for our team in the labs.

Our branches in East Antrim, Strabane, Belfast and Bangor have continued to do a fantastic job of raising money and awareness in their areas, and I'm really grateful for their continued efforts. Many of their members have been raising money for the charity for decades, doing events year after year, which I know takes a lot of time and effort on the part of many.

A busy calendar of in house and supporter events resulted in the decision to extend the contract for Collette, our third pair of hands in the office for another year. We had big plans for spring and summer 2020 with our usual calendar of events all over the country but unfortunately the pandemic managed to stop all of those in their tracks.

Amongst the mentioned events there have been many other runs, walks, hikes, coffee mornings, big breakfasts and we are hugely grateful for every single one. We understand the organisation they require; the amount of time volunteers dedicate and how valuable each pound donated is. I have been to many of these events, and participated in some. I don't personally need any reminding of the awfulness of blood cancer, but I am always struck by the huge impact it has on people, whether those who have lost a loved one or those who know someone who has survived. I am also struck by the generosity of so many who want to do something to make a difference, and run some sort of fundraiser for LLNI. I've met many amazing, inspirational and brave people over the year, who are often struggling to deal with their loss, or finding living with cancer so very hard and my heart goes out to them. This is what keeps us doing what we do, to try to stop this terrible impact on lives for the future. So, thank you for your continued support. Thank you for helping to make last year such a success, and please stay with us as we build on this for the year ahead.

The end of this shortened financial year saw us enter one of the most adverse and challenging periods we have ever seen in the charity and research world. In mid-March our offices were closed and our team adapted quickly in managing the charity and the research remotely. This was also a hugely alarming time for blood cancer patients and their families as those with haematological conditions were quickly identified as extremely vulnerable to the virus. The response from the patient support community, consultants, clinical nurse specialists and GP's was phenomenal and most certainly played a huge part in keeping everyone safe whilst managing illness and treatment in a new way.

Research has never proven so valuable and we were proud to see Chair of Experimental Haematology Professor Ken Mills receive a grant to undertake covid research with some of the blood cancer research team in the early weeks.

Unfortunately, the pandemic is very much still with us and still presenting further challenges several months later but we are grateful our organisation has been able to adapt and overcome many of these and we have not been forced to review any of our current commitments.

This again would not be possible without the ongoing support from the public in NI and further afield and for that we are extremely grateful.

# Leukaemia & Lymphoma NI

## Trustees' report

### **Review of branch activities and developments**

Leukaemia & Lymphoma NI had 3 branches in the province during the year as follows:

- Bangor
- East Antrim
- Strabane

Each branch conducts its own fund raising activities which include such activities as street collections, craft fairs, sponsored walks, dinner dances.

Funds are also generated through donations, many in memory of someone who has died from a blood cancer, or from families where someone has been diagnosed with a blood cancer.

Other sources include interested individuals, organisations and legacies.

### **Medical Advisory Committee**

A Medical Advisory Committee is responsible for recommending to LLNI's Central Committee suitable research programmes. Based upon the advice of the Medical Advisory Committee of LLNI, financial support is provided to the Blood Cancer Research Group (BCRG) at Queen's University Belfast. LLNI supports the laboratory work of two Principal Investigators (Professor Ken Mills & Dr Lisa Crawford) who lead small groups of researchers working on various haematological disease.

### **Professor Ken Mills**

Professor Ken Mills is Chair of Experimental Haematology within the blood cancer research group. His research is focused on Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS) using high density micro arrays, miRNA and epigenetic profiling. These assays involve the simultaneous analysis of large numbers of RNA or miRNAs targets with the aim of disease classification, improving prognostic markers and identifying and screening novel therapies.

Professor Mills is Chair of EU COST Action entitled "European Genomic and Epigenetic Study on MDS and AML", a consortium of laboratories in 22 EU countries. He is also lead for the Belfast Experimental Cancer Medicine Centre (ECMC), Head of the Experimental Cancer Medicine Research Division in the PGJCCR and Academic Lead for the Core Technology Units in the School of Medicine. Professor Mills is a member of the Executive Committees of the Northern Ireland Cancer Registry and Northern Ireland Cancer Trials Centre. Professor Mills sits on the Scientific Review Committee of the Northern Ireland BioBank and the Northern Ireland Cohort Study for the Longitudinal Study of Ageing (NICOLA). He is a regional committee member of the Royal College of Pathologists and an Examiner for the Clinical Scientist programme.

LLNI NI have awarded Professor Mills and infrastructure grant which has been used to fund travel to research workshops, conferences and meetings, small items of equipment and contributes to consumables for all projects within the HRG.



# Leukaemia & Lymphoma NI

## Trustees' report

### **Research Report – Professor Ken Mills**

I would like to begin this report by thanking Leukaemia & Lymphoma NI for their continued support for the Blood Cancer Research Group with the Patrick G Johnston Centre for Cancer Research (PGJCCR) based in Queen's University Belfast.

Blood cancer has the 5th highest incidence of all cancers and surprisingly has the 3rd highest number of deaths. The number of cases of blood cancer is around 1200 per year, but this is probably an under-estimate as the cancer registry does not collect data on several sub-types including MDS. There are three main sub-groups: leukaemia; lymphoma and myeloma, with around 130 different sub-types within the blood cancer umbrella.

The BCRG in Belfast has had a long record of research into some of these sub-types include acute myeloid leukaemia (AML), myelodysplastic syndromes (MDS), chronic myeloid leukaemia (CML), myeloproliferative neoplasms (MPN) and myeloma. The laboratory research focus remains on these, except for CML, however, we also have an active research programme on chronic lymphoid leukaemia (CLL) run in collaboration with colleagues in the Trust.

The BCRG is represented by Professor Ken Mills, with interests in AML and MDS, and Dr Lisa Crawford, who has a focus on myeloma. The CLL work is coordinated by Dr Mark Catherwood, a clinical scientist in the BHSCT, whilst we also have academic partners in the PGJCCR and the Centre for Experimental Medicine (CEM), the Centre for Public Health (CPH) and the School of Pharmacy working with the BCRG on specific projects as highlighted in the text below. The wider group also benefits from clinical interaction with Professor Mary Frances McMullin (AML, MDS and MPN), Dr Jeremy Hamilton (AML) and Dr Sarah Lawless and Professor Curly Morris (myeloma).

The laboratory research themes can be summarised as being (a) the understanding of molecular abnormalities on blood cancer development and (b) novel and repurposed therapies and therapeutic combinations for the myeloid malignancies and myeloma. These themes utilise molecular genetics, genomic and transcriptomic studies, drug screens and medicinal chemistry.

In addition to this we have approved two external applications for research projects also taking place at QUB. The first project by Dr Fiona Furlough was approved to investigate RNA methylation in AML, this would complement the existing epigenetic studies that were underway within the BCRG. The second grant to Professor David Gonzalez, was to develop validate a next generation sequencing platform that will contribute the diagnosis of lymphoid diseases. This will both extend the potential diagnostic capability for these diseases but the data on retrospective samples will contribute to the understanding of the disease, and response to therapies.

The charity funded three PhD students who started in October 2019, James Boncan, Deirdra Venney and Paul Strain.

We welcomed the return of Dr Kathryn Clarke, a clinical scientist who joined the team to manage the newly launched MyBLOCK project, unfortunately she later left in April 2020 to take up the role in the Belfast Trust and but she has been replaced by Dr Lauren Cairns who had previously worked in the group funded by the Little Princess Trust.

# Leukaemia & Lymphoma NI

## Trustees' report

We continue to publish our research and several of these papers arose from work that was done under the LLNI Golden Anniversary awards. Our work has been mostly presented virtually in 2020 including at the European Haematology Association, British Society for Haematology, ESH AML and MPN workshops, International Workshop on Myeloma and EMBO workshops. We also obtained funding from the MDS UK to fund a studentship who commenced in June 2020. Prof Mills, with Prof Ultan Power in the Centre for Experimental Medicine, were awarded two grants from UKRI and NI R&D division of the PHA for identification of repurposed drugs for covid-19. As a result, Dr Ali moved from one of our CCLG grants for a period of 1 year to work on covid-19 and will return to the haematology labs in April 2021.

Anne Jordan, funded by LLNI from many years, continues to undertake assessment of stem cell harvest quality for blood cancer patients and who processes the diagnostic samples for in the Northern Ireland Biobank contributing to the around 900 samples now in the bank.

Anne will also take on more of an active role within the NI Biobank focusing specifically on blood cancer samples

The PGJCCR was closed for all research due to covid-19 from mid-March 2020 until mid-June 2020. This had an obvious impact on the laboratory research potential during this period. The BCRG moved rapidly to online laboratory meetings, supervisory meetings, and research planning meetings. The staff and students continued to analyse data that they had produced in the period prior to closure and lockdown. In many cases, computers were relocated from the PGJCCR offices to their homes to facilitate this analysis. In addition, all students and post-doctoral fellows were tasked with working on manuscripts of their research or literature review. As a result, over 5 papers and 4 reviews were written and submitted with several published during September – November 2020. The laboratory research recommenced in June with a shift pattern adhering to the distancing requirements. Three new PhD students started during this period and have adapted well to the restrictions. The closures meant that the summer studentship programme was suspended. However, recent operational recovery regulations have meant that 3-people per laboratory bay can be accommodated this will allow the inclusion of master level students in the laboratory from early November 2020. All research projects have been affected by the pause, but the impact on these and the studentships is being monitored particularly in view of any future restrictions and centre closures.

As ever, I want to thank the members of the Blood Cancer research group; not only for their contributions to the research but also always being “willing” to be photographed, videoed, interviewed, posted on social media or talking to patients, families, the public and fundraisers to maintain that vital connection between the science and our dedicated supporters.

Finally, to everybody involved with the Leukaemia & Lymphoma NI – thank you. Thank you to the branches and supporters for spending their evenings and weekends raising money to enable us to undertake our research. Thank you for the “behind-the-scenes” team of Claire Gilmore, Collette McMorro and Joanne Badger for all their work linking the fund-raising, public awareness, the committee and the research team. Thank you to the LLNI committee for their continued support and belief in the research we are undertaking. In particular, I need to thank Chairman Richard Buchanan and the Past and Current Chairman of the Medical and

# Leukaemia & Lymphoma NI

## Trustees' report

Scientific Advisory Committee, Professor Curly Morris and Professor Terry Lappin for their support and interest in the research progress.

I know I have said it before, but it is worth repeating, the LLNI is a charity based in Northern Ireland funding research in Northern Ireland which is having a global impact.

## **Core Tissue Support**

LLNI provides core tissue culture support through an annual grant for laboratory infrastructure support for experiments involving cellular and molecular biological techniques.

## **Studentships**

LLNI continues to fund various PhD students and Post-Doctoral Students. In 2019-2020 it funded 3 PhD students and consumables support for another. This funding continues in 2020-2021 with 2 additional PhD students receiving funding.

## **Summer Studentships**

LLNI continues to support five summer studentships in the PGJCCR. The students contribute to a number of projects being undertaken by the Haematology Research Group.

## **Financial review**

Details of the results for the year are set out in the statement of financial activities on pages 16 - 25 and the related notes.

# Leukaemia & Lymphoma NI

## Trustees' report

### Investment policy and returns

LLNI's investments are managed by Cunningham Coates Stockbrokers Belfast and were valued at £1,145,753 as at 31 March 2020.

During the past financial year, we have received dividend income from these investments totalling £63,674 which is most satisfactory.

The Central Committee of LLNI are very pleased with the relationship formed with Cunningham Coates Stockbrokers and their expertise in dealing with our investments.

### Reserves

The Trustees have reviewed the resources of LLNI taking into consideration the variable natures of its income and the need to fulfil the fixed commitment of grant to Queen's University as formalised and confirmed to the University for the period 1 October to 30 September in each year.

### Governance and Internal Control

The organisation structure of LLNI is as set out in the Constitution of LLNI at paragraph 10:

"The following officers, all of whom shall be honorary, that is to say a Patron, a Chairperson, one or more Vice Chairpersons and a Treasurer. Officers shall be elected annually in such a manner and shall discharge such duties as LLNI in general meeting shall from time to time determine."

The major risks to which LLNI would be exposed are centred around the following areas:

***i. Misuse and misappropriation of funds coupled with poor financial controls.***

LLNI's objective is to raise money to finance appropriate research into the causes and possible cures for leukaemia, lymphoma, myeloma and other associated blood cancers. This research is controlled, supervised and vetted by LLNI's Medical Advisory Committee (MAC) under the Chairmanship of Professor T Lappin, assisted by a group of eminent academics. Research projects are carefully scrutinised and "peer reviewed" by the MAC before any recommendations are made within the budgetary confines of LLNI.

The funds to support research are carefully controlled by the Central Committee of LLNI, which received a financial report by the honorary treasurer at each meeting of the Central Committee which meets several times a year under the Chairmanship of Mr Richard Buchanan.

***ii. Lack of proper public liability insurance to cover fund raising activities by members and the possibility of legal action against members.***

Members' fund raising activities are covered for public liability by LLNI's insurance brokers. Members have been circularised that any activity which has the slightest element of risk must have the approval of the insurers before proceeding. High risk activities are not permitted.

## Leukaemia & Lymphoma NI

Trustees' report

### **Auditors**

Hill Vellacott have expressed their willingness to continue in office as auditors and a resolution for their re-appointment will be proposed at the Annual General Meeting.

By order of the board on 9 December 2020.

Mr Richard Buchanan  
*Chairman*

# Leukaemia & Lymphoma NI

## Statement of trustees' responsibilities

The constitution of Leukaemia & Lymphoma NI requires the trustees to prepare financial statements for each financial period which give a true and fair view of the state of affairs of LLNI and of the surplus or deficit of LLNI for that period. In preparing those financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that LLNI will continue in business.

The trustees are responsible for maintaining proper accounting records which disclose with reasonable accuracy at any time the financial position of LLNI and to enable them to ensure that the financial statements comply with the Charities Act (Northern Ireland) 1964 and the Charities (Northern Ireland) Order 1987. They have general responsibility for taking such steps as are reasonably open to them to safeguard the assets of LLNI and to prevent and detect fraud and other irregularities.

The trustees of the Charity who held office at the date of approval of these financial statements, as set out on page 1, each confirm so far as we are aware that:

- there is no relevant audit information of which the Charity's auditors are unaware; and
- we have taken all the steps that we ought to have taken as directors in order to make ourselves aware of any relevant audit information and to establish that the Charity's auditors are aware of that information.

By order of the board on 9 December 2020

Mr Richard Buchanan  
*Chairman*

## Independent auditors' report to the members of Leukaemia & Lymphoma NI

We have audited the financial statements of Leukaemia & Lymphoma NI for the period ended 31 March 2020 which comprise statement of Statement of Financial Activities, Statement of Financial Position, the Statement of Cash Flows and the related notes. These financial statements have been prepared under the historical cost convention and the accounting policies set out therein.

This report is made solely to LLNI's trustees, as a body, in accordance with the Charities Act (Northern Ireland) 1964 and the Charities (Northern Ireland) Order 1987. Our audit work has been undertaken so that we might state to LLNI's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than LLNI and LLNI's members as a body, for our audit work, for this report, or for the opinions we have formed.

### **Respective responsibilities of trustees and auditors**

As described in the Statement of Trustees' Responsibilities LLNI's trustees are responsible for the preparation of financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom General Accepted Accounting Practice).

Our responsibility is to audit the financial statements in accordance with relevant legal and regulatory requirements and International Standards on Auditing (UK and Ireland).

We report to you our opinion as to whether the financial statements give a true and fair view and are properly prepared in accordance with the Charities Act (Northern Ireland) 1964 and the Charities (Northern Ireland) Order 1987. We also report to you if, in our opinion, the Trustees' Report is not consistent with the financial statements, if LLNI has not kept proper accounting records, if we have not received all the information and explanations we require for our audit, or if information specified by law regarding trustees' remuneration and transactions with LLNI is not disclosed.

We read the Trustees' Report and consider the implications for our report if we become aware of any apparent misstatement within it.

### **Basis of audit opinion**

We conducted our audit in accordance with International Standards on Auditing (UK and Ireland) issued by the Auditing Practices Board. An audit includes examination, on a test basis, of evidence relevant to the amounts and disclosures in the financial statements. It also includes an assessment of the significant estimates and judgements made by the trustees in the preparation of the financial statements, and of whether the accounting policies are appropriate to LLNI's circumstances, consistently applied and adequately disclosed.

We planned and performed our audit so as to obtain all the information and explanations which we considered necessary in order to provide us with sufficient evidence to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or other irregularity or error. In forming our opinion, we also evaluated the overall adequacy of the presentation of information in the financial statements.

Independent auditors' report to the members of Leukaemia & Lymphoma NI  
(continued)

**Opinion**

In our opinion, the financial statements give a true and fair view, in accordance with United Kingdom Generally Accepted Accounting Practice, of the state of LLNI's affairs as at 31 March 2020 and of the incoming resources and application of resources for the year then ended. The financial statements have been properly prepared in accordance with the Charities Act (Northern Ireland) 1964 and the Charities (Northern Ireland) Order 1987.

In our opinion the information given in the Trustees' Report is consistent with the financial statements.

**Hill Vellacott**  
Statutory Auditor  
*Chartered Accountants*



## Leukaemia & Lymphoma NI

### Statement of Financial Activities (including Income and Expenditure Account) Period ended 31 March 2020

	Note	Unrestricted funds £	Restricted funds £	2020 Total £	2019 Total £
<b>Income and Endowments</b>					
Income from charitable activities					
Donations and gifts	2	431,449	-	431,449	293,068
Legacies	3	77,355	-	77,355	2,111
Activities for generating funds	4	70	-	70	284
Stem cell harvest		-	-	-	12,000
Investment income	5	41,076	-	41,076	70,174
Sundry Income		-	-	-	-
Profit/(loss) on disposal of investments		(48,646)	-	(48,646)	7,437
<b>Total incoming resources</b>		<b>501,304</b>	<b>-</b>	<b>501,304</b>	<b>385,075</b>
<b>Resources expended</b>					
Cost of generating funds					
Fundraising trading: Cost of goods sold and other costs		1,000	-	1,000	994
Charitable expenditure					
Grants towards:					
– salaries		187,164	-	187,164	353,531
– supplies and equipment		152,363	-	152,363	155,202
– travelling expenses		10,189	-	10,189	22,234
Charitable activities	7	86,157	-	86,157	78,821
<b>Total resources expended</b>		<b>436,873</b>	<b>-</b>	<b>436,873</b>	<b>609,851</b>
<b>Net resources expended</b>		<b>64,431</b>	<b>-</b>	<b>64,431</b>	<b>(224,776)</b>
Movement on valuation of investments		(94,951)	-	(94,951)	(58,301)
<b>Net movement in funds</b>		<b>(30,520)</b>	<b>-</b>	<b>(30,520)</b>	<b>(283,077)</b>
Fund balances brought forward		1,406,335	-	1,406,335	1,689,412
<b>Fund balance carried forward</b>		<b>1,375,815</b>	<b>-</b>	<b>1,375,815</b>	<b>1,406,335</b>

LLNI has no recognised gains or losses other than those included on the preceding page and therefore no separate statement of total recognised gains and losses has been presented.

The incoming resources and resources expended amounts as stated on the preceding page are derived solely from continuing operations.

The notes on pages 17 to 22 form part of these financial statements.

# Leukaemia & Lymphoma NI

## Statement of Financial Position

31 March 2020

	<i>Note</i>	<b>2020</b>		2019	
		£	£	£	£
<b>Fixed assets</b>					
Intangible fixed assets			<b>790</b>		790
Investments at market value	9		<b>1,145,753</b>		1,293,843
<b>Current assets</b>					
Stock		-		1,000	
Prepayments		<b>1,729</b>		3,488	
Cash at bank	10	<b>360,687</b>		215,712	
			<b>362,416</b>	220,200	
<b>Current liabilities</b>					
Accruals		<b>(133,144)</b>		(108,498)	
<b>Net current assets</b>					
			<b>229,272</b>	111,702	
			<b>1,375,815</b>	1,406,335	
<b>Funds</b>					
Unrestricted funds - general funds	12		<b>627,452</b>	525,791	
- designated funds			<b>748,363</b>	880,544	
Restricted funds			<b>1,375,815</b>	1,406,335	

The financial statements were approved by the Trustees on 19 December 2020 and signed on its behalf by:

Mr Richard Buchanan  
*Chairman*

The notes on pages 17 to 22 form part of these financial statements.

# Leukaemia & Lymphoma NI

## Statement of Cash Flows

31 March 2020

	2020 £	2019 £
<b>Cash flows from charitable activities</b> (loss) / surplus for the financial year	<b>(30,520)</b>	(284,008)
<i>Adjustments for:</i>		
Interest received	<b>(299)</b>	(458)
Movement on valuation of investments	<b>94,998</b>	58,508
(Loss) / Gain on disposal of investments	<b>48,646</b>	(7,437)
Accrued expenses	<b>24,646</b>	12,291
<i>Changes in:</i>		
Stock	<b>1,000</b>	-
Prepayments	<b>1,759</b>	(2,073)
Cash generated from charitable activities	<b>140,230</b>	(222,247)
Interest received	<b>299</b>	458
Net cash from charitable activities	<b>140,529</b>	(221,789)
<b>Cash flows from investing activities</b>		
Purchase of shares	<b>(23,943)</b>	(281,730)
Proceeds from sale of shares	<b>248,431</b>	269,096
Net cash used in investing activities	<b>365,017</b>	(234,423)
<b>Net increase/(decrease) in cash and cash equivalents</b>		
<b>Cash and cash equivalents at beginning of year</b>	<b>252,609</b>	487,032
<b>Cash and cash equivalents at end of year</b>	<b>617,626</b>	252,609
<b>Cash and cash equivalents</b>		
Cash at bank	<b>360,687</b>	215,712
Investment cash accounts	<b>256,892</b>	36,897
	<b>617,579</b>	252,609

# Leukaemia & Lymphoma NI

## Notes

*forming part of the statement of accounts*

### **1 Accounting policies**

The accounting policies are consistent with those of the previous year.

#### **(i) Basis of accounting**

LLNI prepares its financial statements under historical cost convention, as modified by the inclusion of investments at market value. The financial statements have been prepared in accordance with the Charities SORP (FRS 102).

#### **(ii) Fund accounting**

General funds are unrestricted funds which are available for use at the discretion of the trustees in furtherance of the general objectives of the charity and have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by LLNI for particular purposes. The cost of raising and administering such funds are charged against the specific fund.

Designated funds are unrestricted funds that have been set aside by the trustees for particular purposes. Details of the designated funds are described in note 12.

Investment income and gains are allocated to the unrestricted fund.

#### **(iii) Incoming resources**

All incoming resources are included in the statement of financial activities when the charity is legally entitled to the income and the amount can be quantified with reasonable accuracy. For legacies, entitlement is the earlier of the charity being notified of an impending distribution or the legacy being received.

Gifts in kind donated for distribution are included at valuation and recognised as income when they are distributed to the projects. Gifts donated for resale are included as income when they are sold. Donated facilities are included at the value to the charity where this can be quantified and a third party is bearing the cost. No amounts are included in the financial statements for services donated by volunteers.

Due to the nature of donated income, such income is not capable of control by LLNI and branches before receipt. However, financial controls are in place to ensure accurate recording and safeguarding of all income received by LLNI.

# Northern Ireland Leukaemia Research Fund

Notes (continued)

## 1 Accounting policies (continued)

### (iv) Resources expended

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category.

Grants payable for research are included in the statement of financial activities when approved by the trustees after review by a medical advisory committee. The value of grants unpaid at the year end is accrued.

Management and administration costs are those incurred in connection with administration of the charity and compliance with constitutional and statutory requirements.

### (v) Investments

Investments are stated at market value at the balance sheet date. The statement of financial activities includes the net gains and losses arising on revaluations and disposals throughout the year.

## 2 Donations and gifts

	Unrestricted £	Restricted £	2020 £	2019 £
Income from general donations	401,747	-	401,747	258,786
Gift Aid	5,696	-	5,696	8,135
<b>Branches</b>				
Bangor and district	7,068	-	7,068	5,214
East Antrim	16,938	-	16,938	20,933
	<u>431,449</u>	<u>-</u>	<u>431,449</u>	<u>293,068</u>

## 3 Legacies

	2020 £	2019 £
From the estate of:		
E. Rea	5,000	-
G. Quirk	60,024	-
M.C. Eastwood	12,331	-
D. Euston	-	500
Corry Legacy	-	500
A.M. Crawford	-	111
H. Killops	-	1,000
	<u>77,355</u>	<u>2,111</u>

All the legacies are unrestricted.

# Northern Ireland Leukaemia Research Fund

Notes (continued)

## 4 Sale of Goods

Promotional items such as pens, T-shirts, wedding favours, badges and wrist bands are sold on the website [leukaemia&lymphomani.org](http://leukaemia&lymphomani.org).

## 5 Investment income

	2020 £	2019 £
Bank interest	299	458
Other interest	2,785	6,042
Dividends	37,992	63,674
	<hr/>	<hr/>
	<b>41,076</b>	70,174
	<hr/> <hr/>	<hr/> <hr/>

## 6 Staff numbers and costs

LLNI had no employees during the year. LLNI pays grants to Queen's University towards the salaries of employees working on leukaemia research.

## 7 Charitable activities

	2020 £	2019 £
Insurance	721	1,110
Audit and accountancy	3,900	3,940
Legal	1,449	-
Events management	31,393	22,952
Sundry expenses	2,704	279
Promotion and advertising	34,701	33,565
Investment management charges	4,734	10,843
Bank fees	739	310
Telephone	391	461
Computer costs	3,892	1,326
Subscriptions	853	3,104
Donations	434	-
Bank interest	47	-
Repairs	199	-
	<hr/>	<hr/>
	<b>86,157</b>	77,890
	<hr/> <hr/>	<hr/> <hr/>

# Northern Ireland Leukaemia Research Fund

Notes (continued)

## 8 Net outgoing resources

Net outgoing resources are stated after charging:

	2020 £	2019 £
Auditors' remuneration	3,900	3,940

## 9 Fixed asset investments

	2020 £	2019 £
At 1 August 2019	1,256,946	1,295,383
Additions at cost	23,942	281,730
Disposal proceeds	(248,431)	(269,303)
(Loss) / Profit on disposal	(48,646)	7,437
Revaluation	(94,951)	(58,301)
	<u>888,860</u>	<u>1,256,946</u>
Monies held	256,892	36,897
	<u>1,145,752</u>	<u>1,293,843</u>
<b>At 31 March 2020</b>	<b>1,145,752</b>	<b>1,293,843</b>

## 10 Cash at bank

	2020 £	2019 £
Current account	261,091	102,868
Branch bank accounts	3,158	17,278
Special interest bearing account	92,559	92,435
Petty cash	-	20
Held in PayPal account	3,879	3,111
	<u>360,687</u>	<u>215,712</u>
<b>At 31 March 2020</b>	<b>360,687</b>	<b>215,712</b>

# Northern Ireland Leukaemia Research Fund

Notes *(continued)*

## 11 Branch Donations received and transfers to central account

Branch	Opening bank balance 01/08/19	Net Donations Lodged to Bank £	Expenses £	Amount transferred to central account £	Closing bank balance 31/03/20 £
East Antrim	17,278	16,938	(58)	(31,000)	3,158
	<hr/>	<hr/>	<hr/>	<hr/>	<hr/>
	17,278	16,938	(58)	(31,000)	3,158
	<hr/>	<hr/>	<hr/>	<hr/>	<hr/>



## Northern Ireland Leukaemia Research Fund

Notes (continued)

### 12 Unrestricted funds

	Balance at 1 August 2019	Transfer to / (from) designated funds	Income	Expenses	Balance at 31 March 2020
	£		£	£	£
General reserves	525,791	(217,435)	549,950	(230,854)	627,452
<b>Designated funds</b>					
Stem Cell Harvest	19,413	(7,337)	-	(10,685)	1,391
General account for consumables	18,958	9,553	-	(21,219)	7,292
Core tissue culture support	18,959	11,179	-	(22,846)	7,292
Grade 4 clerical officer	23,334	586	-	(23,920)	-
Haematology	111,667	(14,073)	-	(42,739)	54,855
NILRF Coordinator expenses	31,577	(3,150)	-	(28,427)	-
Mosaic Study	16,666	-	-	(16,666)	-
Karyo Sequencing	-	50,000	-	(16,650)	33,350
Stipend and Consumables	-	17,257	-	(17,257)	-
My BLOck	-	150,000	-	(26,073)	123,927
Clinical trials nurse	46,774	(10,699)	-	(27,482)	8,593
PhD Studentship	-	20,019	-	(20,019)	-
PhD Studentship	111,762	(7,652)	-	(23,198)	80,911
Research Fellow	338,839	-	-	-	338,839
Research Studentship	1,600	(825)	-	(775)	-
Studentship	98,842	(3,073)	-	(25,356)	70,413
Foy Grant	-	-	-	-	-
Research Grant	16,667	3,333	-	(5,487)	14,513
Clerical Officer	25,486	2,317	-	(20,815)	6,988
	<u>1,406,335</u>	<u>-</u>	<u>549,950</u>	<u>(580,070)</u>	<u>1,375,815</u>

The general reserve fund represents those funds which are unrestricted and not designated for other purposes.

The designated funds have been set aside by LLNI for the department of Haematology, PGJCCR, mainly to aid with the administration of research projects.